Quince Therapeutics, Inc. (QNCX) Stock Score, Valuation & Financial Research

Quince Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for QNCX

Quince Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 31.73. These figures are a research snapshot, not a buy or sell recommendation.

What Quince Therapeutics, Inc. does

Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Quince Therapeutics is a late-stage biotechnology company focused on developing innovative therapeutics for rare diseases. The company currently operates as a research and development entity and does not generate revenue from product sales, relying instead on capital raises and financing arrangements to fund its clinical trials and operations.

Products and services

  • The company is developing EryDex, a proprietary automated intracellular drug encapsulation system, primarily targeting the treatment of Ataxia-Telangiectasia.

Brands and product families

  • EryDex — Automated intracellular drug encapsulation system for rare diseases. Source

Customer types

Patients with rare diseases.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on various third-party CROs to conduct and manage its clinical trials. Source

Business strengths to evaluate

  • Proprietary EryDex technology platform Source

Business risks and research considerations

  • History of operating losses and need for additional capital Source
  • Clinical trial failure or delays Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

QNCX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 31.73
Market capitalization:
8.83M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -92.48M
Free cash flow:
USD -41.78M
Cash:
USD 115.98M
Total debt:
USD 18.47M
EPS:
USD -68.91

What stands out

  • Free cash flow is USD -41.78M, negative for the stored period.
  • The balance sheet shows USD 115.98M of cash versus USD 18.47M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 97.51M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for QNCX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can QNCX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is QNCX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for QNCX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of QNCX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research QNCX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.